Last reviewed · How we verify
Genetic-Tailored AntiThrombotic Strategy
A personalized anticoagulation strategy that tailors antithrombotic therapy selection based on individual genetic and clinical factors to optimize efficacy and safety.
A personalized anticoagulation strategy that tailors antithrombotic therapy selection based on individual genetic and clinical factors to optimize efficacy and safety. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment, Acute coronary syndrome management.
At a glance
| Generic name | Genetic-Tailored AntiThrombotic Strategy |
|---|---|
| Sponsor | Texas Cardiac Arrhythmia Research Foundation |
| Drug class | Genetic-guided anticoagulation/antiplatelet therapy strategy |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This approach uses genetic testing and patient-specific characteristics to guide the choice and dosing of anticoagulant or antiplatelet agents, rather than applying a one-size-fits-all treatment paradigm. By identifying genetic variants affecting drug metabolism (such as CYP2C9, VKORC1, or CYP3A4 polymorphisms) and other individual risk factors, the strategy aims to reduce thrombotic events while minimizing bleeding complications.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism prevention and treatment
- Acute coronary syndrome management
Common side effects
- Bleeding (major or minor)
- Thrombotic events
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: